Exfoliating Acids and Barrier Care Patents: Leaders & Trends 2026
Exfoliating Acids and Barrier Care Patents: Who Holds Ground and Where It's Open
26.1% concentration at the top. The five leading assignees account for 641 of the 2,457 records in scope, with a long tail of single- and low-filing entrants behind them. Filings rose from 60 in 2017 to a peak of 228 in 2022, then eased; the 2021-to-2024 window shows a 17% decline (152 to 126). 2025 and 2026 counts are understated because publication typically lags filing by around 18 months.
- 1SUNSHINE LAKE PHARMA CO LTD7.7%
- 2PROCTER & GAMBLE CO7.4%
- 3IMMUNOGEN INC5.3%
- 4LUPIN LTD3.0%
- 5SPOGEN BIOTECH INC2.6%
See the full exfoliating acids and barrier care analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents on exfoliating acid and barrier care formulations?
The assignee ranking in this dataset shows one filer well ahead of the rest, holding 190 records against 65 at fifth place and 48 at tenth. The five leading assignees together account for 26.1% of all 2,457 records in scope, and the top ten reach 36.8%. Beyond that, the field spreads across a long tail of lower-volume filers, so a competitive check should look past just the top names.
Is patent filing in this area still growing?
Filing volume rose from 60 records in 2017 to a peak of 228 in 2022, then eased; the 2021-to-2024 window shows a 17% decline from 152 to 126. That said, 2025 and 2026 figures are understated because publication typically lags filing by around 18 months, so it is too early to call this a sustained downturn rather than a plateau after a filing surge.
What is the difference between a pharmaceutical and a cosmetic filing in this space?
In this dataset, 71.6% of records carry an A61K medicinal-preparations classification versus 29.2% for A61Q cosmetics use, meaning many tolerance and delivery innovations for exfoliating acids are still claimed through pharmaceutical language even when marketed as cosmetics. The representative filing in this landscape, US20060269495A1, is itself framed as a pharmaceutical composition for treating skin disorders rather than a cosmetic product, which affects how its claims read against a purely cosmetic formulation.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Exfoliating Acids and Barrier Care covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.